Eli Lilly's Quarter Confirms Who Is Winning Obesity Care

Second-quarter revenue rose 48 percent to $23 billion, prompting a fresh guidance raise, even as Novo Nordisk’s oral pill keeps the weight-loss race far from settled.

Key Takeaways

• Revenue climbed to $22.97 billion, well above Wall Street’s $20.73 billion estimate, and Lilly raised full-year revenue guidance to $85 billion through $87 billion, its second increase this year.
• Foundayo, Lilly’s new obesity pill, generated $98 million in its debut quarter, a soft start next to Novo Nordisk’s oral Wegovy, which has already crossed three million prescriptions.
• Shares rose nearly 6 percent before the opening bell, closing in on Lilly’s 52-week high, just as Medicare’s new GLP-1 coverage program begins reshaping U.S. demand.

A Beat Already Priced In

Eli Lilly’s second quarter arrived exactly as the market had come to expect: enormous, and still not quite large enough to end the argument about what comes next. Revenue rose 48 percent to $22.97 billion, well past the $20.73 billion consensus, while non-GAAP earnings per share reached $8.38 against an estimate near $6.01. For a stock already trading on the assumption of category dominance, a beat of that magnitude functions less as revelation than as ratification. The number that mattered more sat further down the release: Lilly raised its full-year revenue guidance to a range of $85 billion to $87 billion, up from $82 billion to $85 billion, its second upward revision of the year.

That distinction, between beating a quarter and revising a year, is where the real story of this earnings season lives. Shares had fallen nearly 5 percent just days earlier on no particular news, a pullback that said more about a valuation with no margin for disappointment than about the underlying business. Options markets had priced in a swing of almost 7 percent around the release. What Lilly delivered was not a surprise so much as an answer to a question the market had already framed for itself: could growth this fast still be accelerating. The guidance raise says yes, and investors, who have learned to treat this company’s forecasts as conservative by habit, will spend the next quarter finding out whether that habit still holds.

The Engine Beneath the Number

Strip away the headline and the quarter is really a story about two drugs and one disappointment. Mounjaro, Lilly’s diabetes treatment, brought in $9.9 billion worldwide, up 91 percent, with international sales more than doubling on the strength of its addition to China’s national reimbursement list earlier this year. Zepbound added $4.9 billion in the United States alone, up 44 percent, as prescription volume overwhelmed a deliberate reduction in cash-pay pricing. These are not incremental gains. They are the arithmetic of a company that has, in the space of three years, built the largest franchise in pharmaceutical history from a molecule that barely existed as a commercial product before 2022.

Foundayo, the oral pill approved in April, tells a quieter and more instructive story. It generated $98 million in its first quarter of sales, just shy of the roughly $103 million analysts had modeled, a gap too small to alarm anyone but too persistent to ignore. The reason sits at a rival across the Atlantic. Novo Nordisk’s own oral pill, an updated version of Wegovy, launched in January and had already surpassed three million American prescriptions by June, one of the fastest pharmaceutical launches on record. Lilly still commands the larger share of the injectable market by a wide margin, but the pill category, the one both companies are counting on to pull in patients who have never touched a needle, currently belongs to Novo. That is the uncomfortable footnote inside an otherwise commanding quarter.

Discipline Inside the Expansion

What distinguishes this quarter from earlier ones is not growth, which has become almost routine, but the composure with which Lilly is managing its cost structure while growth compounds. Non-GAAP gross margin reached 86.3 percent of revenue, an improvement of 1.3 percentage points, on better production economics and a richer product mix that offset weaker pricing. Research and development spending rose 14 percent to $3.8 billion, a restrained figure for a company mid-launch on multiple fronts, while marketing and administrative costs climbed 25 percent to support Foundayo’s early push and Mounjaro’s continued international rollout. None of this reads as a company straining under its own success.

Beneath the operating line, the picture turns busier and less tidy, by design rather than accident. Acquired research charges reached $2.8 billion, up from $154 million a year ago, tied to the purchases of Orna Therapeutics and Ajax Therapeutics, while $703 million in restructuring costs reflected the integration of Kelonia Therapeutics and Centessa Pharmaceuticals. Both deals closed within the quarter. Since then, Lilly has added three companies to build an infectious disease portfolio, agreed to acquire AtaiBeckley, and committed a further $4.5 billion to expand manufacturing capacity in Indiana. This is a company spending its scale on optionality, betting that a share of these acquisitions will matter as much in five years as tirzepatide does today.

Building Past Tirzepatide

The quarter’s most consequential news for long-term investors was not a sales figure at all. Retatrutide, Lilly’s next-generation triple agonist, completed its Phase 3 program with positive results across obesity, obstructive sleep apnea, and knee osteoarthritis pain, giving the company a full data package and a stated intent to file for approval in early 2027. This is the molecule meant to succeed Mounjaro and Zepbound once patents and competition begin to weigh on both, and a completed trial program more than a year ahead of filing is the kind of certainty that valuation models reward well before the drug reaches a pharmacy shelf.

Smaller regulatory wins filled out the rest of the picture. The FDA approved a less frequent dosing schedule for Ebglyss in atopic dermatitis, the European Commission cleared Jaypirca as a standalone treatment for chronic lymphocytic leukemia, and Lilly filed for a type 2 diabetes indication for orforglipron, broadening Foundayo’s eventual reach beyond weight management alone. Even Jardiance, a decade-old partnership with Boehringer Ingelheim, contributed a $250 million milestone payment, a reminder that Lilly’s older businesses still generate real cash even as newer ones absorb the market’s attention.

The Market’s Verdict, the Policy Tailwind

Investors answered quickly and without much ambiguity. Shares rose roughly 5.7 percent in premarket trading, pushing toward $1,180 and narrowing the distance to the stock’s 52-week high near $1,249. That reaction fell squarely within what options markets had priced ahead of the release, evidence that the quarter met rather than exceeded already elevated expectations, which in this market counts as a genuine achievement. Analyst sentiment, already tilted heavily toward buy ratings with price targets clustered above $1,270, is unlikely to move much on this print alone. It rarely needs to.

The more durable tailwind arrived from Washington rather than Wall Street. On July 1, the Centers for Medicare and Medicaid Services began a demonstration program giving eligible Medicare Part D beneficiaries access to Foundayo, Zepbound, and Wegovy at a $50 monthly copay, a policy shift that could meaningfully widen the patient population for both companies over the next eighteen months. Novo Nordisk, for its part, posted second-quarter sales of roughly $12 billion, a fraction of Lilly’s total, and its shares fell nearly 5 percent despite raising its own forecast. The obesity market remains large enough for both firms to grow. This quarter simply confirmed, once again, which one is growing faster.